| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Jonathan M. Adams | EVP Liver Cirrhosis Programs | $82,185 | 02 Feb 2022 | ||
| Penelope Markham | EVP Liver Cirrhosis R&D | $80,851 | 16 Feb 2023 | ||
| Steve Gorlin | Director | $78,345 | 09 Nov 2023 | ||
| Cuong Do V | President & CEO, Director | $71,342 | 05 Jan 2026 | ||
| Christopher Reading | EVP Neuroscience R&D | $62,780 | 16 Feb 2023 | ||
| Clarence N. Ahlem | EVP Neuroscience Product Dev. | $62,780 | 16 Feb 2023 | ||
| Richard J. Berman | Director | $19,265 | 20 Nov 2024 | ||
| Amy Suzon Chappell | Director | 05 Jan 2026 | |||
| Sigmund Rogich | Director | 05 Jan 2026 | |||
| Kameel D. Farag | Director | 05 Jan 2026 | |||
| Michael Edward Sherman | Director | 05 Jan 2026 | |||
| Terren S. Peizer | Director, 10%+ Owner | 23 Nov 2022 | |||
| James Paul Lang | Director | 05 Jan 2026 | |||
| Joseph M. Palumbo MD | Chief Medical Officer | 05 Jan 2026 | |||
| Joanne Wendy Kim | Chief Financial Officer | 05 Jan 2026 | |||
| Robert J. Hariri | Director | 20 Nov 2024 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Joseph M. Palumbo MD | BIVI | Stock Option (right to buy) | Award | 132,000 | 132,000 | 05 Jan 2026 | Direct | |||
| Joanne Wendy Kim | BIVI | Stock Option (right to buy) | Award | 110,100 | 110,100 | 05 Jan 2026 | Direct | |||
| Sigmund Rogich | BIVI | Stock Option (right to buy) | Award | 211,100 | 141,100 | 05 Jan 2026 | Direct | |||
| Cuong V Do | BIVI | Stock Option (right to buy) | Award | 665,300 | 665,300 | 05 Jan 2026 | See Footnote | |||
| Michael Edward Sherman | BIVI | Stock Option (right to buy) | Award | 421,100 | 341,100 | 05 Jan 2026 | Direct | |||
| Kameel D. Farag | BIVI | Stock Option (right to buy) | Award | 57,500 | 57,500 | 05 Jan 2026 | Direct | |||
| Amy Suzon Chappell | BIVI | Stock Option (right to buy) | Award | 57,500 | 57,500 | 05 Jan 2026 | Direct | |||
| James Paul Lang | BIVI | Stock Option (right to buy) | Award | 420,500 | 330,500 | 05 Jan 2026 | Direct | |||
| Cuong V Do | BIVI | Common Stock | Purchase | 100.2% | 5,000 | 9,992 | 07 Aug 2025 | See Footnote | ||
| Cuong V Do | BIVI | Warrants (right to buy) | Purchase | 10000% | 5,000 | 5,050 | 07 Aug 2025 | See Footnote |